DBVT - DBV Technologies S.A.
10.92 0.00 (0.00%)
After hours: 4:15PM EST
| Previous close | 11.09 |
| Open | 10.91 |
| Bid | 10.98 x 800 |
| Ask | 11.00 x 2200 |
| Day's range | 10.91 - 11.10 |
| 52-week range | 6.08 - 13.49 |
| Volume | 155,331 |
| Avg. volume | 341,673 |
| Market cap | 1.057B |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.27 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.12 |
- Zacks
DBV Technologies is in Overbought Territory: What???s Next?
DBV Technologies has moved higher as of late, but there could definitely be trouble on the horizon for this company.
- Simply Wall St.
Does Market Volatility Impact DBV Technologies S.A.'s (EPA:DBV) Share Price?
Anyone researching DBV Technologies S.A. (EPA:DBV) might want to consider the historical volatility of the share...
- Simply Wall St.
If You Had Bought DBV Technologies (EPA:DBV) Stock Three Years Ago, You'd Be Sitting On A 71% Loss, Today
DBV Technologies S.A. (EPA:DBV) shareholders should be happy to see the share price up 18% in the last month. But that...
- Motley Fool
Here's Why Aimmune Therapeutics Fell 7% Today
The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.
- Zacks
DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Zacks
DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in DBV Technologies S.A. (DBVT).
- Motley Fool
Why DBV Technologies Shares Soared Today
Traders cheered after the company announced the pricing details of a stock offering.
- Business Wire
Cohen Milstein Sellers & Toll PLLC Announces Investigation of DBV Technologies S.A.
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.
- Business Wire
Cohen Milstein Announces Investigation of DBV Technologies S.A.
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.
- Business Wire
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against DBV Technologies S.A. (DBVT)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) securities between February 14, 2018 and December 19, 2018, inclusive (the “Class Period”). DBV Technologies investors have until March 18, 2019 to file a lead plaintiff motion.
- Simply Wall St.
Is DBV Technologies S.A. (EPA:DBV) Potentially Underrated?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! DBV Technologies S.A. (EPA:DBV) is a stock Read More...
- GlobeNewswire
DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019
Montrouge, France, February 4, 2019 DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 Novel immunotherapy based on Viaskin technology highlighted as a potential treatment for ...
- Business Wire
Robbins Arroyo LLP: DBV Technologies S.A. (DBVT) Sued for Misleading Shareholders
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of DBV Technologies S.A. filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 14, 2018 and December 19, 2018.
- Business Wire
DBVT INVESTOR NOTICE: Rosen Law Firm Reminds DBV Technologies S.A. Investors of Deadline in First Filed Securities Class Action – DBVT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of DBV Technologies S.A. from February 14, 2018 through December 19, 2018, inclusive of the important March 18, 2019 lead plaintiff deadline in the first-filed class action.
- GlobeNewswire
DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference
Montrouge, France, February 1, 2019 DBV Technologies to Present at the 8 th Annual Leerink Partners Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: ...
